X

Trial Profile

A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Bullous pemphigoid
Focus Adverse reactions
Sponsors Akari Therapeutics

Most Recent Events

10 May 2022 Results presented in an Akari Therapeutics media release.
04 May 2022 Results published in the JAMA Dermatology
22 Apr 2021 According to an Akari Therapeutics media release, results from this trial will be presented in a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience (VMX) 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com